Skip to content

Harmony Biosciences

US · HRMY #2681 by market cap Listed 2020
32.59 -0.39 -1.18%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Quant vs Street three independent views, side by side

StockVane factor grade
A+
Momentum strategy signal
Sell
Analyst consensus
Buy

Mostly aligned, one view stands apart.

Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.

✦ Quant Analyst Revision Trend how this is computed

Deteriorating
2
■ Upgrades■ Downgrades
  • 0 upgrades vs 2 downgrades among tracked analyst rating changes.
  • Most recent: UBS moved from Buy to Hold on 2026-02-20.

Analyst consensus 8 analysts

Buy
Avg price target 47.50 +45.8%
Price target rangecurrent 32.59
Low30.00
Avg47.50
High60.00
Buy 63% Hold 25% Sell 13%
Recent ratings (25)
DateFirmAnalystRatingTarget
2026-11-12 H.C. Wainwright -- Buy 55.00
2026-11-06 UBS -- Hold 39.00
2026-11-05 H.C. Wainwright -- Buy 55.00
2026-11-04 H.C. Wainwright -- Buy 55.00
2026-11-03 H.C. Wainwright -- Buy 55.00
2026-10-29 Mizuho Securities -- Buy 49.00
2026-10-27 H.C. Wainwright -- Buy 55.00
2026-10-19 Needham -- Buy 50.00
2026-10-15 Ladenburg Thalmann -- Buy 55.00
2026-10-13 H.C. Wainwright -- Buy 55.00
2026-10-12 Mizuho Securities -- Buy 51.00
2026-10-12 BofA Securities -- Sell 30.00
2026-10-01 Deutsche Bank -- Hold 42.00
2026-09-25 Mizuho Securities -- Buy 51.00
2026-09-24 Needham -- Buy 50.00
2026-08-26 Wolfe Research -- Buy 60.00
2026-08-12 H.C. Wainwright -- Buy 55.00
2026-08-05 Mizuho Securities -- Buy 51.00
2026-08-05 Deutsche Bank -- Hold 39.00
2026-08-04 Mizuho Securities -- Buy 51.00
2026-08-04 BofA Securities -- Sell 30.00
2026-08-04 Needham -- Buy 50.00
2026-08-04 H.C. Wainwright -- Buy 55.00
2026-07-31 Mizuho Securities -- Buy 51.00
2026-07-27 Mizuho Securities -- Buy 50.00

Price target trend monthly average, last 3 years

Recent rating changes

DateFirmChangeTarget
2026-02-20 UBS Buy → Hold 46.00
2026-02-19 Truist Financial Buy → Hold --

Earnings history price reaction on the day

PeriodReport dateSessionOptions expectedActual move
2026/Q3 2026-11-04 -- ±15.14% -7.04% (in line)
2026/Q2 2026-08-04 -- ±16.79% +8.93% (in line)
2026/Q1 2026-05-07 -- ±14.03% -4.15% (in line)
2025/Q4 2026-02-24 -- ±14.00% +4.91% (in line)
2025/Q3 2025-11-04 -- ±11.00% +4.74% (in line)
2025/Q2 2025-08-05 -- ±17.96% -1.69% (in line)
2025/Q1 2025-05-06 -- ±13.45% +6.98% (in line)
2024/Q4 2025-02-25 -- ±13.47% +8.16% (in line)
2024/Q3 2024-10-29 -- ±16.69% +16.06% (in line)
2024/Q2 2024-08-06 -- ±23.30% +6.18% (in line)
2024/Q1 2024-04-30 -- ±13.46% +5.68% (in line)
2023/Q4 2024-02-22 -- ±17.42% -4.70% (in line)

"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.

Quote time 2026-11-20 20:02:36 · For reference only, not investment advice and not tailored to your situation.

Harmony Biosciences discussion 0 comments

Add a comment